CASIA OpenIR  > 中国科学院分子影像重点实验室
PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
Li, Yuan1,2; Du, Yang3; Sun, Ting1,2; Xue, Huadan1,2; Jin, Zhengyu1,2; Tian, Jie3
Source PublicationBMC CANCER
ISSN1471-2407
2018-06-19
Volume18Pages:7
Corresponding AuthorJin, Zhengyu(jin_zhengyu@163.com) ; Tian, Jie(jie.tian@ia.ac.cn)
AbstractBackground: Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate the potential of monoclonal antibody against T cell checkpoint PD-1 in combination with chemotherapeutic drug ZA in BC mouse model. Methods: The 4 T1-fLuc mouse BC model was used in this study. The anti-tumor efficacy of anti-PD-1 antibody alone or in combination with ZA was monitored by measuring bioluminescence imaging (BLI) and tumor volume. At the end of study, the flow cytometry was used to determine the immune cell population in tumors after different treatment. Results: The results showed that mice treated with the combination therapy of anti-PD-1 antibody plus ZA exhibited better antitumor response compared to untreated controls or single therapy with no obvious toxicity. Conclusion: Our study provides preclinical evidence for the enhanced BC treatment benefit through targeting co-signal molecules by combining anti-PD-1 antibody plus ZA treatment.
KeywordPD-1 Zoledronic acid Breast cancer Therapy Checkpoint inhibitior
DOI10.1186/s12885-018-4412-8
WOS KeywordCHECKPOINT INHIBITORS ; PHASE-3 TRIAL ; OPEN-LABEL ; METASTASES ; ANTIBODY ; THERAPY ; LIGAND ; SAFETY
Indexed BySCI
Language英语
Funding ProjectNational Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[61231004] ; National Natural Science Foundation of China[81171390] ; Key Projects in the National Science & Technology Pillar Program[2012BAI23B06] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science & Technology Commission[Z161100002616022]
Funding OrganizationNational Natural Science Foundation of China ; Key Projects in the National Science & Technology Pillar Program ; Strategic Priority Research Program from Chinese Academy of Sciences ; International Innovation Team of CAS ; Beijing Municipal Science & Technology Commission
WOS Research AreaOncology
WOS SubjectOncology
WOS IDWOS:000435892200004
PublisherBIOMED CENTRAL LTD
Citation statistics
Cited Times:1[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/23180
Collection中国科学院分子影像重点实验室
Corresponding AuthorJin, Zhengyu; Tian, Jie
Affiliation1.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Radiol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
2.Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China
3.Chinese Acad Sci, Inst Automat, State Key Lab Management & Control Complex Syst, Key Lab Mol Imaging CAS, 95 ZhongGuanCun East Rd, Beijing 100190, Peoples R China
Corresponding Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Recommended Citation
GB/T 7714
Li, Yuan,Du, Yang,Sun, Ting,et al. PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model[J]. BMC CANCER,2018,18:7.
APA Li, Yuan,Du, Yang,Sun, Ting,Xue, Huadan,Jin, Zhengyu,&Tian, Jie.(2018).PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.BMC CANCER,18,7.
MLA Li, Yuan,et al."PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model".BMC CANCER 18(2018):7.
Files in This Item: Download All
File Name/Size DocType Version Access License
LY_BMC_Cancer_2018.p(4369KB)期刊论文作者接受稿开放获取CC BY-NC-SAView Download
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Li, Yuan]'s Articles
[Du, Yang]'s Articles
[Sun, Ting]'s Articles
Baidu academic
Similar articles in Baidu academic
[Li, Yuan]'s Articles
[Du, Yang]'s Articles
[Sun, Ting]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Li, Yuan]'s Articles
[Du, Yang]'s Articles
[Sun, Ting]'s Articles
Terms of Use
No data!
Social Bookmark/Share
File name: LY_BMC_Cancer_2018.pdf
Format: Adobe PDF
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.